Skip to main content

Table 2 Clinical outcomes in patients receiving maintenance therapy in the RemIT-JAV-RPGN study

From: Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis

 

Relapse and/or difficulty reducing GC (n = 14)

Sustained remission without difficulty reducing GC (n = 31)

p valued

Male/female, n/n

9/5

9/22

0.047

Age, years

68 (61–72)

68 (61–77)

0.60

GPA/MPA, n/n

3/11

11/20

0.49

MPO-ANCA-positive before treatment

13 (93%)

25 (81%)

0.41

PR3-ANCA-positive before treatment

1 (7%)

7 (23%)

0.4

BVAS score before treatment

18 (11–25)

15 (12–18)

0.31

Glucocorticoids, mg/day

 At 6 months

15 (11–18)

13 (10–17)

0.19

 At 12 months

12 (10–14)

7 (5–10)

< 0.001

 At 18 months

11 (10–15)

5 (5–8)

< 0.001

Immunosuppressants

7 (50%)

18 (58%)

0.75

AZA/MTX/others, n

4/1/2

13/0/10

 

Serum creatinine at 6 months, mg/dL

1.00 (0.83–2.09)

0.86 (0.70–1.02)

0.053

eGFR at 6 months, mL/min/1.73 m2

43 (21–74)

61 (46–72)

0.3

CRP at 6 months, mg/dL

0.09 (0.006–0.43)

0.05 (0.01–0.17)

0.96

MPO-ANCA at 6 months, U/mLa

1.3 (1–2)

1 (0.4–2.6)

0.42

MPO-ANCA negative conversion at 6 monthsb

10 (83%)

14 (61%)

0.48

TIMP-1 at 6 months, ng/mL

176 (159–216)

144 (135–168)

0.004

High TIMP-1 at 6 monthsc

13 (93%)

13 (42%)

0.003

  1. Values are medians (IQR) or n (%)
  2. aOnly MPO-ANCA-positive patients whose MPO-ANCA levels were measured at 6 months (relapse and/or difficulty reducing GC, n = 13; sustained remission without difficulty reducing GC, n = 25)
  3. bThe rate of MPO-ANCA negative conversion was only calculated for MPO-ANCA-positive patients whose MPO-ANCA levels were measured at 6 months (relapse and/or difficulty reducing GC, n = 12; sustained remission without difficulty reducing GC, n = 23)
  4. cSerum TIMP-1 levels at 6 months ≥ 150 ng/mL
  5. dp < 0.05 was considered to be significant
  6. GC, glucocorticoids; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase-3; ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score version 3; AZA, azathioprine; MTX, methotrexate; eGFR, estimated glomerular filtration rate; TIMP-1, tissue inhibitor of metalloproteinase 1